



## News Release

### **Suven's partnering and fund-raising activity at J.P. Morgan Healthcare Conference 2011**

**HYDERABAD, INDIA (Jan 11, 2011) – Suven Life Sciences** is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets in CNS disorders for unmet medical needs with \$20 billion market potential, today announced that it is participating at **29<sup>th</sup> J.P. Morgan Healthcare Conference** being held in **San Francisco, USA** during **10<sup>th</sup> to 13<sup>th</sup> Jan 2011**.

J.P. Morgan Healthcare conference is the premier conference of its kind, bringing together established industry leaders, emerging fast-growth companies, innovative technology creators and globally minded service providers who will deliver presentations to more than 4,000 investors. This conference puts you at the center of the investment and partnering community and provides an open format to connect with the funding partners.

With the targeted audience of senior executives and industry leaders from pharmaceutical, biotechnology and venture capital communities, **J.P. Morgan Healthcare Conference** provides the greatest opportunity for relationship building, facilitating discussions on financing opportunities with an unparalleled opportunity to create new value generating partnerships.

Mr.Venkat Jasti CEO of Suven is scheduled to discuss the company's corporate overview, business strategy, **fund raising and partnering activity for their Phase 2a ready clinical candidate SUVN-502 for cognition in Alzheimer's and Schizophrenia** at the **J.P. Morgan Healthcare Conference 2011** where the world's top notch investment professionals will present along with the most innovative companies who are decision makers.

The Company has twelve (12) internally discovered therapeutic drug candidates **currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity** in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

For more information on Suven/ACT, please visit our Web site at <http://www.suven.com>

#### **Risk Statement:**

***Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;***